Merck today announced its submission for a Food and Drug Administration emergency use authorization of its investigational oral antiviral COVID-19 medicine. The drug, molnupiravir, is meant for the treatment of mild-to-moderate COVID-19 in at-risk adults. According to Merck, an interim analysis of its ongoing phase 3 clinical trial yielded positive results for non-hospitalized adult patients with mild-to-moderate COVID-19 who were at risk for progressing to severe COVID-19 and/or hospitalization; according to the data, molnupiravir reduced the risk of hospitalization or death by approximately 50%.

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Chairperson's File
Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…